Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei September 3, 2024 12:15 CET Regulatory Read more
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) September 3, 2024 12:00 CET Regulatory Read more
Invitation to the presentation of Calliditas´s interim report January – June 2024 August 5, 2024 07:00 CET Non Regulatory Read more
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy July 26, 2024 17:00 CET Non Regulatory Read more
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis July 26, 2024 08:00 CET Regulatory Read more
Launch of Phase 3 clinical trial with Nefecon in Japan July 4, 2024 08:30 CET Non Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) June 17, 2024 17:30 CET Regulatory Read more
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy May 30, 2024 20:00 CET Regulatory Read more
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress May 28, 2024 14:00 CET Non Regulatory Read more
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation May 28, 2024 08:30 CET Regulatory Read more
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO’s Mode of Action May 16, 2024 16:30 CET Non Regulatory Read more
Invitation to the presentation of Calliditas´s interim report January – March 2024 May 16, 2024 08:30 CET Non Regulatory Read more
Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm May 15, 2024 14:00 CET Non Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) May 15, 2024 12:00 CET Regulatory Read more
Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China May 14, 2024 13:00 CET Non Regulatory Read more
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib May 6, 2024 08:00 CET Regulatory Read more
Calliditas Announces Positive NefIgArd Open Label Extension Results April 24, 2024 08:30 CET Non Regulatory Read more
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 April 18, 2024 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to Attend Conferences in April April 9, 2024 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 – 16 in Buenos Aires April 8, 2024 14:00 CET Non Regulatory Read more
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment April 8, 2024 09:00 CET Non Regulatory Read more
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® March 6, 2024 08:15 CET Regulatory Read more
Calliditas Therapeutics to Attend Investor Conferences in March March 1, 2024 13:00 CET Non Regulatory Read more
Invitation to the presentation of Calliditas´ Year-end report January – December 2023 February 14, 2024 07:00 CET Non Regulatory Read more
Calliditas Therapeutics provides business update ahead of JP Morgan conference January 8, 2024 08:15 CET Regulatory Read more
Calliditas Therapeutics appoints Maria Törnsén as President North America January 7, 2024 17:00 CET Non Regulatory Read more
Calliditas to present at JP Morgan Healthcare Conference January 7, 2024 15:00 CET Non Regulatory Read more
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital December 27, 2023 17:45 CET Regulatory Read more
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function December 20, 2023 22:15 CET Regulatory Read more
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO® December 11, 2023 15:15 CET Regulatory Read more
Calliditas announces additions to the management team December 1, 2023 09:00 CET Regulatory Read more
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome November 30, 2023 08:30 CET Non Regulatory Read more
Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy November 24, 2023 08:45 CET Non Regulatory Read more
Calliditas to present at upcoming investor conferences November 7, 2023 16:00 CET Non Regulatory Read more
Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023 November 6, 2023 21:30 CET Non Regulatory Read more
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy October 27, 2023 09:15 CET Non Regulatory Read more
Calliditas Therapeutics’ nomination committee composition for the AGM 2024 October 23, 2023 15:00 CET Regulatory Read more
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 October 19, 2023 08:00 CET Non Regulatory Read more
European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas’ application for setanaxib in Alport syndrome October 5, 2023 10:30 CET Non Regulatory Read more
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy October 3, 2023 09:20 CET Non Regulatory Read more
Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023 September 29, 2023 14:00 CET Non Regulatory Read more
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU September 28, 2023 12:01 CET Non Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib September 27, 2023 19:06 CET Non Regulatory Read more
Calliditas Therapeutics to Present Nefecon Data at the 17[th] International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo September 19, 2023 16:00 CET Non Regulatory Read more
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy August 18, 2023 10:00 CET Regulatory Read more
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet August 15, 2023 08:00 CET Non Regulatory Read more
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib July 13, 2023 08:00 CET Non Regulatory Read more
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO[®] June 21, 2023 09:00 CET Non Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 30, 2023 16:00 CET Regulatory Read more
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 May 5, 2023 14:30 CET Non Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 28, 2023 08:30 CET Regulatory Read more
Calliditas to participate in upcoming investor conferences March 31, 2023 17:00 CET Non Regulatory Read more
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy March 12, 2023 18:30 CET Regulatory Read more
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy February 2, 2023 09:15 CET Non Regulatory Read more
Number of shares and votes in Calliditas Therapeutics January 31, 2023 08:00 CET Regulatory Read more
China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy December 30, 2022 08:30 CET Non Regulatory Read more
Number of shares and votes in Calliditas Therapeutics December 30, 2022 08:00 CET Regulatory Read more
Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2019/2022 December 20, 2022 21:15 CET Non Regulatory Read more
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan December 13, 2022 08:00 CET Regulatory Read more
Calliditas to host fireside chat with its China commercial partner, Everest Medicines December 9, 2022 08:00 CET Non Regulatory Read more
Calliditas’ partner Everest Medicine’s New Drug Application for Nefecon is accepted by the China NMPA November 15, 2022 08:00 CET Non Regulatory Read more
Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape November 7, 2022 09:00 CET Non Regulatory Read more
Calliditas Therapeutics’ nomination committee composition for the AGM 2023 October 21, 2022 10:00 CET Regulatory Read more
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy October 19, 2022 15:30 CET Non Regulatory Read more
Calliditas’ partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy September 20, 2022 14:00 CET Non Regulatory Read more
European Commission approves Kinpeygo® for adults with primary IgA nephropathy July 15, 2022 17:00 CET Regulatory Read more
Calliditas announces additions to the management team July 11, 2022 12:30 CET Non Regulatory Read more
Calliditas Therapeutics establishes a U.S. At-the-Market Program June 28, 2022 23:15 CET Non Regulatory Read more
Issuance and repurchase of C-shares to establish an at-the-market program June 20, 2022 21:15 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 19, 2022 16:30 CET Regulatory Read more
Calliditas receives positive CHMP opinion in IgA nephropathy May 19, 2022 14:30 CET Regulatory Read more
First patient randomized in Phase 2 trial in head and neck cancer May 17, 2022 11:00 CET Non Regulatory Read more
Calliditas Therapeutics to participate in upcoming investor conferences May 10, 2022 08:30 CET Non Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 14, 2022 08:30 CET Regulatory Read more
Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2018/2022 March 24, 2022 12:00 CET Non Regulatory Read more
Calliditas provides a regulatory update on EMA process for Nefecon March 22, 2022 08:00 CET Non Regulatory Read more
Expansion of Everest Medicine’s licence agreement to include South Korea March 14, 2022 07:00 CET Non Regulatory Read more
First patient randomized in pivotal TRANSFORM study with setanaxib February 15, 2022 10:30 CET Non Regulatory Read more
Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™ January 28, 2022 08:00 CET Non Regulatory Read more
FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy December 15, 2021 21:45 CET Non Regulatory Read more
Calliditas announces poster presentations at ASN Digital Kidney Week 2021 November 3, 2021 08:00 CET Non Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2022 November 2, 2021 10:00 CET Regulatory Read more
Calliditas announces acquisition of remaining Genkyotex minority shares October 7, 2021 08:00 CET Non Regulatory Read more
Updated regulatory timeline for review of MAA in Europe. September 16, 2021 14:30 CET Regulatory Read more
PDUFA goal date extension for Nefecon NDA in the U.S. September 14, 2021 21:10 CET Regulatory Read more
Number of shares and votes in Calliditas Therapeutics August 31, 2021 09:00 CET Non Regulatory Read more
Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million August 12, 2021 23:55 CET Regulatory Read more
Calliditas Therapeutics intends to carry out a directed share issue August 12, 2021 17:04 CET Regulatory Read more
Calliditas Receives FDA Fast Track Designation for setanaxib in PBC August 9, 2021 08:00 CET Non Regulatory Read more
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe July 21, 2021 08:45 CET Regulatory Read more
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency May 28, 2021 14:40 CET Regulatory Read more
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference May 28, 2021 12:00 CET Non Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 27, 2021 18:30 CET Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021 May 14, 2021 14:00 CET Non Regulatory Read more
Calliditas promotes Andrew Udell to President, North America May 3, 2021 14:30 CET Non Regulatory Read more
FDA grants priority review for Nefecon, for patients with IgA nephropathy April 28, 2021 09:50 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 26, 2021 12:00 CET Regulatory Read more
EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy April 23, 2021 08:30 CET Regulatory Read more
Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy March 15, 2021 07:30 CET Regulatory Read more
Calliditas strengthens its US Commercial and Medical Affairs Organization March 8, 2021 08:30 CET Non Regulatory Read more
Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice March 4, 2021 14:30 CET Non Regulatory Read more
First Patient Dosed in NefIgArd Open Label Extension Study February 4, 2021 08:30 CET Non Regulatory Read more
Calliditas announces termination of the proposed global offering January 28, 2021 14:40 CET Regulatory Read more
Calliditas Therapeutics launches proposed global offering January 26, 2021 22:10 CET Regulatory Read more
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial January 21, 2021 08:30 CET Non Regulatory Read more
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day January 20, 2021 08:00 CET Regulatory Read more
Positive Phase 1 results in high-dose setanaxib trial January 18, 2021 08:00 CET Non Regulatory Read more
Agenda for Calliditas virtual R&D Day on January 20, 2021 January 15, 2021 09:00 CET Non Regulatory Read more
Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex December 16, 2020 17:47 CET Non Regulatory Read more
Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 December 9, 2020 13:00 CET Non Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2021 November 27, 2020 16:00 CET Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report November 11, 2020 11:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial November 9, 2020 10:00 CET Non Regulatory Read more
Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial November 8, 2020 12:45 CET Regulatory Read more
Calliditas closes acquisition of a controlling interest in Genkyotex SA November 3, 2020 15:15 CET Regulatory Read more
Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 October 19, 2020 08:00 CET Non Regulatory Read more
The 200[th] patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 October 1, 2020 09:45 CET Non Regulatory Read more
Number of shares and votes in Calliditas Therapeutics September 30, 2020 10:00 CET Regulatory Read more
First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon September 8, 2020 08:00 CET Non Regulatory Read more
Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA August 13, 2020 07:00 CET Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report August 11, 2020 14:00 CET Non Regulatory Read more
Exercise of over-allotment option and end of the stabilization period July 2, 2020 08:45 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) June 25, 2020 18:30 CET Regulatory Read more
Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market June 24, 2020 22:45 CET Regulatory Read more
CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas June 22, 2020 08:00 CET Non Regulatory Read more
Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market June 12, 2020 23:00 CET Regulatory Read more
Calliditas Therapeutics prices its initial public offering on The Nasdaq Global Select Market in the United States June 5, 2020 08:40 CET Regulatory Read more
Calliditas Therapeutics launches US IPO roadshow and targets a capital raise of MUSD 75 June 1, 2020 13:00 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) May 26, 2020 12:00 CET Regulatory Read more
Calliditas publicly files registration statement with SEC for a proposed initial public offering in the United States May 14, 2020 15:00 CET Regulatory Read more
Calliditas provides a corporate business update in the context of the Covid-19 pandemic April 27, 2020 08:00 CET Non Regulatory Read more
Calliditas strengthens its US Commercial Organization April 1, 2020 08:00 CET Non Regulatory Read more
Calliditas moves its Annual General Meeting 2020 to June 25 March 30, 2020 14:00 CET Regulatory Read more
Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ) March 3, 2020 12:45 CET Regulatory Read more
Notice of extraordinary general meeting of Calliditas Therapeutics AB (publ) January 31, 2020 08:30 CET Regulatory Read more
Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN January 22, 2020 08:00 CET Non Regulatory Read more
Calliditas submits draft registration statement for the listing of ADSs in the U.S. January 9, 2020 17:35 CET Regulatory Read more
The pivotal Phase 3 clinical trial NefIgArd Part A fully recruited December 23, 2019 08:00 CET Non Regulatory Read more
Completion of recruitment of Part A of the NeflgArd pivotal Phase 3 clinical trial by year end December 19, 2019 08:00 CET Regulatory Read more
China IND approval triggers $5 million milestone payment from Everest Medicines December 17, 2019 11:40 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2020 November 11, 2019 10:00 CET Regulatory Read more
Calliditas Therapeutics Capital Markets Day today November 4 November 4, 2019 08:00 CET Non Regulatory Read more
Save the date: Calliditas to host Capital Markets Day in Stockholm on November 4, 2019 October 1, 2019 13:00 CET Non Regulatory Read more
Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon October 1, 2019 08:00 CET Regulatory Read more
Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study September 3, 2019 07:00 CET Regulatory Read more
Strategic in-licensing related to autoimmune hepatitis in the US market August 12, 2019 14:40 CET Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q2 report August 12, 2019 12:00 CET Non Regulatory Read more
Calliditas has resolved on a directed share issue in the amount of 3.5 million shares, raising proceeds of approximately SEK 210 million July 3, 2019 08:00 CET Regulatory Read more
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore June 10, 2019 08:00 CET Regulatory Read more
Calliditas Therapeutics to Present at Redeye Growth Day June 4, 2019 13:00 CET Non Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 8, 2019 18:30 CET Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q1 report May 6, 2019 15:00 CET Non Regulatory Read more
Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics April 5, 2019 11:15 CET Non Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 4, 2019 09:01 CET Regulatory Read more
Calliditas Therapeutics to Present at the Needham Healthcare Conference April 3, 2019 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to Present at March Investor Conferences March 4, 2019 10:00 CET Non Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis February 12, 2019 11:15 CET Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis February 5, 2019 10:15 CET Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2018 full-year report February 1, 2019 10:00 CET Non Regulatory Read more
Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs January 14, 2019 14:30 CET Non Regulatory Read more
Calliditas Therapeutics appoints Andrew Udell to VP Commercial, North America January 8, 2019 07:00 CET Non Regulatory Read more
Bulletin from extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ) December 14, 2018 16:15 CET Regulatory Read more
Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ) November 14, 2018 08:00 CET Regulatory Read more
First patient enrolled in pivotal clinical phase 3 study NEFIGARD with lead candidate Nefecon November 13, 2018 16:20 CET Regulatory Read more
Calliditas Therapeutics to present and attend investor conferences in November 2018 November 9, 2018 14:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Q3 2018 Business Update October 30, 2018 08:00 CET Non Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2019 October 4, 2018 10:00 CET Regulatory Read more
Presentation at International IgA Nephropathy Network meeting highlighting supportive post-hoc analysis of the NEFIGAN study October 1, 2018 08:00 CET Non Regulatory Read more
Post-hoc results from NEFIGAN study to be presented at the International IgA Nephropathy Network meeting (IIgANN) September 25, 2018 08:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update August 13, 2018 08:00 CET Non Regulatory Read more
The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts August 6, 2018 08:00 CET Non Regulatory Read more
Calliditas Therapeutics selected to present at the 25th Annual NewsMakers in the Biotech Industry August 1, 2018 08:00 CET Non Regulatory Read more
Exercise of over-allotment option and end of the stabilization period July 29, 2018 18:30 CET Regulatory Read more
Trading in Calliditas’ share commences today on Nasdaq Stockholm June 29, 2018 08:00 CET Non Regulatory Read more
Calliditas announces listing on Nasdaq Stockholm and related prospectus June 15, 2018 05:00 CET Regulatory Read more
Surrogate marker and design of Calliditas Therapeutics’ IgA nephropathy Phase 3 study agreed with the FDA November 20, 2017 09:00 CET Non Regulatory Read more
Pharmalink strengthens its management team. Appoints new Chief Financial Officer and head of communications August 15, 2017 15:40 CET Non Regulatory Read more
Positive Phase 2b Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy presented at Leading Kidney Disease Conference July 4, 2017 15:39 CET Non Regulatory Read more
Positive Phase 2b Trial of Pharmalink’s Nefecon in IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference May 31, 2017 15:38 CET Non Regulatory Read more
Pharmalink AB announces the appointment of a new Chief Executive Officer May 18, 2017 15:38 CET Non Regulatory Read more
Positive results of Phase 2b Clinical Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy published in The Lancet March 29, 2017 15:36 CET Non Regulatory Read more
Pharmalink strengthens team in preparation for Phase III trials with Nefecon in IgA Nephropathy, a progressive inflammatory kidney disease December 12, 2016 15:34 CET Non Regulatory Read more
Pharmalink announces European orphan drug designation for Nefecon® for treatment of IgA Nephropathy, an inflammatory kidney disease November 29, 2016 15:31 CET Non Regulatory Read more
Pharmalink announces positive result in Phase 2b Trial of Nefecon® April 14, 2015 15:30 CET Non Regulatory Read more
Pharmalink announces an open Investigational New Drug (IND) application for Nefecon® January 21, 2015 15:30 CET Non Regulatory Read more
Data from clinical study of Pharmalink’s Nefecon® to be presented at American Society of Nephrology’s Kidney Week 2014 November 3, 2014 15:27 CET Non Regulatory Read more
Pharmalink extends patent protection for Nefecon® treatment for renal disease October 27, 2014 15:27 CET Non Regulatory Read more
Pharmalink’s core patents for Nefecon® treatment for renal disease granted in United States, Europe, China and Hong Kong July 10, 2014 15:26 CET Non Regulatory Read more
Pharmalink completes enrolment of patients into Phase IIB clinical study (NEFIGAN) of Nefecon® January 13, 2014 15:25 CET Non Regulatory Read more
Pharmalink initiates a pivotal Phase IIb trial with Nefecon® in patients with primary IgA nephropathy December 18, 2012 15:24 CET Non Regulatory Read more
Pharmalink enters manufacturing agreement for Nefecon® October 31, 2012 15:23 CET Non Regulatory Read more
Pharmalink AB Receives US Orphan Drug Designation for Nefecon® (PL-56) October 13, 2010 15:14 CET Non Regulatory Read more
Grifols agrees to acquire intellectual property for treatment of post-polio syndrome from Pharmalink AB May 20, 2010 15:13 CET Non Regulatory Read more
Pharmalink AB receives patent for Nefecon® principle. Japanese grant supports Asian partnering program. October 26, 2009 15:10 CET Non Regulatory Read more
Pharmalink AB completes Phase II clinical study with renal disease drug Nefecon April 29, 2009 15:08 CET Non Regulatory Read more
Pharmalink reports promising interim results from phase II trials for new renal disease drug Nefecon® March 31, 2008 15:07 CET Non Regulatory Read more
